8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 2, 2026·SEC
Cocrystal Pharma, Inc.(COCP)Earnings, Financials & Key Ratios
COCP•NASDAQ
$1.02
Price updated Jun 27, 2026
AboutCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.Show more
- Revenue$0
- EBITDA-$9M+51.3%
- Net Income-$9M+49.5%
- EPS (Diluted)-0.78+54.7%
- ROE-111.4%-14.3%
COCP Price & Volume
Cocrystal Pharma, Inc. (COCP) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
"Cocrystal Pharma remains a high-risk, pre-revenue entity heavily reliant on sporadic milestone payments, as evidenced by the isolated $225,000 revenue reported in 2026Q1. The company's reliance on a capital-intensive drug discovery platform has resulted in a significant erosion of shareholder equity, which fell from $26.4 million in 2023Q4 to $4.1 million in 2026Q1. Investors should monitor the company's ability to secure non-dilutive funding, as the current cash position of $4.7 million suggests a rapidly narrowing operational runway."
Verdict Logic
the company's cash position has dwindled to $4.7 million as of 2026Q1, indicating an imminent liquidity shortfall that likely necessitates further dilutive equity financing.
COCP Growth Metrics
Cocrystal Pharma, Inc. (COCP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.87%
Return on Capital
10 Years-59.6%
5 Years-66.34%
3 Years-81.29%
Last Year-97.34%
COCP Recent Earnings
Cocrystal Pharma, Inc. (COCP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 21, 2026Metric
Actual
Est
EPS
$0.16-6.7%
$0.15
Rev
—
—
Q2 2026
May 15, 2026Metric
Actual
Est
EPS
$0.17-13.3%
$0.15
Rev
$225,000+0.0%
$225,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.19+13.6%
$0.22
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.20+33.3%
$0.30
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 21, 2026 | $0.16vs $0.15-6.7% | — |
| Q2 2026 | May 15, 2026 | $0.17vs $0.15-13.3% | $225,000vs $225,000+0.0% |
| Q4 2025 | Nov 14, 2025 | $0.19vs $0.22+13.6% | — |
| Q3 2025 | Aug 14, 2025 | $0.20vs $0.30+33.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cocrystal Pharma, Inc. (COCP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.02 | $10.45M | -1.31 | — | — | -111.4% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $4.58 | $904.72M | -26.94 | 128.21% | 83.95% | 129.32% | — | |
| $60.28 | $850.49M | 66.24 | 20.03% | 14.99% | 13.98% | — | |
| $18.56 | $3.51B | -11.53 | 53.44% | -2554.14% | -43.94% | — | |
| $127.88 | $158.77B | 18.86 | 2.39% | 30.99% | 42.33% | — |
Compare COCP vs Peers
Cocrystal Pharma, Inc. (COCP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COCP SEC Filings & Documents
Cocrystal Pharma, Inc. (COCP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when COCP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
COCP Frequently Asked Questions
Cocrystal Pharma, Inc. (COCP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cocrystal Pharma, Inc.'s revenue?
Cocrystal Pharma, Inc. (COCP) reported $0.2M in revenue for fiscal year 2025.
Is COCP profitable?
Cocrystal Pharma, Inc. (COCP) reported a net loss of $8.8M for fiscal year 2025.
Dividend & Returns
What is COCP's return on equity?
Cocrystal Pharma, Inc. (COCP) has a return on equity (ROE) of -111.4%. Negative ROE indicates the company is unprofitable.
What is Cocrystal Pharma, Inc.'s free cash flow?
Cocrystal Pharma, Inc. (COCP) had negative free cash flow of $7.8M in fiscal year 2025, likely due to heavy capital investments.